Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
Q2 2025 vs. Q1 2025
How the institutions holding Cero Therapeutics Holdings, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 15 | 8 | −7 |
| Shares | 723.1K | 246.8K | −476.3K (−65.9%) |
| Value | $527.7K | $2.38M | +$1.85M (+350.3%) |
New holders (1)
Institutions that held Cero Therapeutics Holdings, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jones Financial Companies LLLP | 3 | $29 | 0.00% |
Sold out (8)
Institutions that held Cero Therapeutics Holdings, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Armistice Capital, LLC | 312,000 | $227.8K |
| Avantax Planning Partners, Inc. | 74,321 | $54.3K |
| Geode Capital Management, LLC | 16,917 | $12.3K |
| Citadel Advisors LLC | 16,218 | $11.8K |
| Susquehanna International Group, LLP | 13,343 | $9.74K |
| Barclays PLC | 102 | $74 |
| Advisor Group Holdings, Inc. | 4 | $2 |
| JPMorgan Chase & Co | 1 | $1 |